面部骨骼假体植入在美容手术中的并发症:系统评价与Meta分析
该系统评价与Meta分析纳入48项研究、3701例患者共4139枚面部骨骼假体,评估术后并发症与失败率。总体并发症率为10.7%(95%CI 8.3%-13.2%),鼻旁假体最高为15.1%,颧骨假体最低为7.4%;硅胶、羟基磷灰石钙和Medpor并发症率分别为2.78%、1.02%和2.48%。结论认为面部骨骼假体是改善面部美观和骨骼增强的可行选择,并发症风险相对较低。
要点
- 面部骨骼假体总体并发症率为10.7%(95%CI 8.3%-13.2%)。
- 鼻旁假体并发症率最高15.1%,颧骨假体最低7.4%。
- 硅胶、羟基磷灰石钙和Medpor并发症率分别为2.78%、1.02%、2.48%。
核心结论
- 面部骨骼假体是改善面部美观和进行面部骨骼增强的可行选择,并发症风险相对较低。
研究设计与样本
- 系统评价与Meta分析,检索Google Scholar和PubMed数据库,纳入48项研究、3701例患者、4139枚假体,使用OpenMeta[Analyst]软件分析。
主要发现
- 总体并发症率为10.7%(95%CI 8.3%-13.2%,I2=89.35%)。
- 鼻旁假体并发症率最高为15.1%(95%CI 7.8%-22.3%),颧骨假体最低为7.4%(95%CI 3.8%-11.1%,I2=72.62%)。
- 硅胶、羟基磷灰石钙和Medpor的并发症率分别为2.78%、1.02%和2.48%。
- 15项颧骨假体研究中853/1788例(45.8%)患者接受颧骨假体(95%CI 0.356-0.561)。
- 8项下颌假体研究中265/508例(56%)患者接受下颌假体(95%CI 0.474-0.645);11项研究中371/489例(76.1%)接受鼻或鼻旁假体(95%CI 0.565-0.912);3项研究中14/15例(85.5%)接受额部假体(95%CI 0.645-0.997);17项颏假体研究中1366/1366例(100%)接受颏假体(95%CI 0.995-1.000,I2=0%)。
关键数值与推荐
- 总体并发症率为10.7%(95%CI 8.3%-13.2%)。
- 鼻旁假体并发症率15.1%(95%CI 7.8%-22.3%),颧骨假体7.4%(95%CI 3.8%-11.1%)。
- 硅胶并发症率2.78%,羟基磷灰石钙1.02%,Medpor 2.48%。
临床怎么用
- 临床选择面部骨骼假体时,可参考不同部位和材料的并发症率进行个体化决策。
- 鼻旁假体并发症率较高,术后需加强监测与随访。
- 硅胶、羟基磷灰石钙和Medpor的并发症率均较低,可作为假体材料选择依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the effectiveness of various alloplastic facial implants in correcting facial defects based on post-operative complications and failure rates in patients who underwent facial skeletal augmentation. METHOD: A comprehensive search for articles reporting relevant articles was using Google Scholar and PubMed databases. Data from publications that satisfied the predefined inclusion criteria were synthesized and analyzed using OpenMeta [Analyst] software. RESULTS: A total of 48 studies with a population size of 3701 patients who received 4139 alloplastic facial implants were included in this analysis. The complication rate was 10.7% (95% confidence intervals [CI] [8.3%, 13.2%], and I2 =89.35%). Paranasal implants had the highest rate of complications of 15.1% (95% CI [7.8%, 22.3%], and malar implants had the lowest complication rate of 7.4% (95% CI 3.8%, 11.1%]) I2 = 72.62%). In 15 studies that had malar implants, 853/1788 (45.8%) of the patients received malar implants (95% CI [0.356, 0.561]). In 8 studies that included mandibular implants, 265 (56%) of 508 patients received mandibular implants (95% CI [0.474, 0.645]); in 11 studies, 371/489 (76.1%) received nasal or paranasal implants (95% CI of [0.565, 0.912]), while in 3 studies, 14/15 (85.5%) received frontal implant (95% CI of [0.645, 0.997]). In 17 studies that investigated the use of chin implants, 1366/1366 (100%) of the eligible patients received chin implants (95% CI [0.995, 1.000], I2 = 0%). The complication rate was 2.78% for silicone, 1.02% for calcium hydroxyapatite, and 2.48 for Medpor. CONCLUSION: Alloplastic facial implants are a viable alternative to enhancing facial beauty and performing facial skeletal augmentation with a relatively lower risk of complications associated with all facial implants.
引用
- Abdulaziz MKB, Kamal M, Kolaityte V, et al. Complications of alloplastic facial skeletal implants in aesthetic surgery: A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2025. PMID: 40499276. doi:10.1016/j.bjps.2025.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。